Objective: Compare the effects of a vaginal estradiol tablet and a vaginal moisturizer, each to placebo, on menopause-related quality of life and mood in postmenopausal women with moderate-severe vulvovaginal symptoms.
B
othersome vulvovaginal symptoms including lack of lubrication and discomfort or pain with vaginal intercourse are prevalent amongst postmenopausal women, [1] [2] [3] with up to 75% reporting vaginal dryness and up to 40% reporting pain with intercourse. 2, 4 Moderate to severe vulvovaginal symptoms in postmenopausal women are associated with significant decreases in sexual functioning 5, 6 and in quality of life (QOL), comparable to the effects of other chronic conditions such as arthritis, asthma, and irritable bowel syndrome. 1 Current treatment options for postmenopausal vulvovaginal symptoms include vaginal treatments 7, 8 such as vaginal estrogen creams, tablets, or rings; vaginal moisturizers; intravaginal prasterone (dehydroepiandrosterone) 9 ; as well as the oral selective estrogen receptor modulator ospemifene.
have demonstrated that vaginal estrogen creams, 11, 12 vaginal estrogen tablets, [13] [14] [15] [16] intravaginal prasterone (dehydroepiandrosterone), 9 and ospemifene 10, 17 reduce vulvovaginal symptoms, although few of these trials have examined the effects of treatment on QOL or mood. Limited data exist to support the use of vaginal moisturizers and no studies have examined their effects on QOL. [18] [19] [20] The Menopause Strategies: Finding Lasting Answers for Symptoms and Health clinical trials network recently completed a three-arm double blind trial of vaginal estradiol tablets, a vaginal moisturizer, and matching placebos for each to examine the efficacy of vaginal estradiol and vaginal moisturizer relative to placebo in improving genitourinary symptoms of menopause. The primary results of that trial showed no benefit over placebo for the vaginal estradiol tablet or moisturizer in reducing severity of most bothersome symptom. 21 Herein we report the effects of vaginal estradiol tablet plus placebo gel or vaginal moisturizer plus placebo tablet versus dual placebo on menopause-related QOL, depressive symptoms, and anxiety.
METHODS

Study design
A randomized, double-blind, placebo-controlled 12-week trial was conducted among women with moderate-severe vulvovaginal symptoms recruited at two sites: Kaiser Permanente Washington Health Research Institute in Seattle, WA and University of Minnesota in Minneapolis, MN. The protocol was approved by the institutional review board at each site and at the Data Coordinating Center. All women provided written informed consent.
The trial enrolled 302 women from April 2016 to February 2017. Women were eligible if they were 45 to 70 years old, 2 or more years since last menses, reported 1 or more moderate-severe symptom of vulvovaginal itching, pain, dryness, or irritation experienced at least weekly within the past 30 days; or pain with penetration at least once monthly. Exclusion criteria included current vaginal infection; use of hormonal medication in past 2 months; use of antibiotics, vaginal moisturizer, probiotic, prebiotic, or douche in past month; and chronic premenopausal vulvovaginal symptoms. Additional details of the trial design and methods were published previously. 21 
Treatment and study procedures
Women were recruited through direct mailings and Facebook ads targeted to women aged 50 to 70 years within 20 miles of the clinical sites. Randomization by permuted blocks of 9 and stratified by site was conducted in a secure Webbased database, and implemented via a computerized inventory system for dispensing identical-appearing tablets in bottles and gel in tubes. Participants, study personnel, and clinical providers were blinded to treatment assignments.
Women were randomly assigned 1:1:1 to vaginal estradiol 10 mcg tablet (Vagifem) þ placebo vaginal gel (hydroxyethyl cellulose); placebo vaginal tablet þ vaginal moisturizer (Replens); or placebo tablet þ placebo gel. The composition of the placebo vaginal gel, vaginal moisturizer, and placebo tablet have been described previously. 21 Women were instructed to use the vaginal tablet (active or placebo) daily for 2 weeks, then twice weekly for the remaining 10 weeks. The vaginal gel (active or placebo) was to be used every 3 days throughout the trial. During the first 2 weeks, participants were advised to use tablet in the morning and gel in the evening. After that participants were instructed to use the products on alternate days.
Data collection
Telephone contact at 1, 3, and 11 weeks postrandomization assessed protocol adherence and adverse events. Follow-up clinic visits were conducted 4 and 12 weeks postrandomization and included completion of questionnaires regarding menopause-specific QOL, mood, and sexual function. At follow-up visits women were asked to bring medications; remaining pills were counted and gel tubes weighed to provide medication adherence estimates.
Outcomes/measurements
Menopause QOL was specified a priori as a secondary outcome, measured as change from baseline to 12 weeks in the total Menopause-Specific Qualify of Life (MENQOL) questionnaire. 22 The MENQOL is a 29-item self-report measure of QOL designed to capture information on the presence and bother of symptoms, feelings, and experiences in the four domains of vasomotor, physical, psychosocial, and sexual functioning among midlife women in the menopause transition, total score range from 1 to 8. For each item, women were asked to report if they had experienced that symptom or feeling in the past 4 weeks, and if they had, to rate bother on a scale of 0 to 6 corresponding to ''not bothered at all'' to ''extremely bothered.'' These two items were combined to create a score from 1 (not experiencing symptoms or feeling) to 8 (extremely bothered). Each domain score was the average of the item scores in that domain (higher scores indicated poorer QOL). Validity, reliability, and responsiveness to change have been shown to be adequate to excellent. 22 In addition, we evaluated mood using the eight-item version of the depression module of the Patient Health Questionnaire (PHQ-8), which asks responders to indicate how often they have been bothered by a variety of symptoms and feelings in the last 2 weeks. The PHQ-8 depression scale is scored continuously with a range from 0 to 24; accepted categories of depression severity are 0 to 4 normal, 5 to 9 mild, and 10 or higher moderate to severe. 23, 24 Anxiety was evaluated using the seven-item Generalized Anxiety Disorder (GAD-7) questionnaire, which also asks responders to indicate how often they have been bothered by specific symptoms or feelings in the previous 2 weeks. The GAD-7 score ranges from 0 to 21, with anxiety severity categorized as 0 to 4 normal, 5 to 9 mild, or 10 or more moderate to severe. 25 
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Other measurements
As previously reported, the primary outcome of the trial was severity of the most bothersome symptom defined by the participant at trial enrollment as vulvovaginal itching, pain, dryness, irritation, or pain with penetration. Severity was rated 0 to 3, signifying none, mild, moderate, or severe. At each visit, women completed a questionnaire about presence and severity of vulvovaginal symptoms. Demographic factors, smoking status, alcohol intake, and health status were assessed by questionnaire at baseline. Additional prespecified secondary outcomes included sexual functioning assessed using the Female Sexual Function Index (FSFI) 26 and the Female Sexual Distress Scale-Revised. 27 
Statistical analysis
A modified intent-to-treat analysis included all randomized participants who provided follow-up QOL, depressive symptoms, or anxiety symptoms data at week 4, week 12, or both, regardless of treatment adherence.
Linear regression models were fit to summarize total MENQOL score, the four MENQOL domain scores, the PHQ-8 score, and the GAD-7 score at both 4 and 12 weeks as a function of treatment assignment, baseline value of the outcome measure, visit, and clinical site. Robust standard errors were calculated using generalized estimating equations to adjust for correlation between repeated outcome measures. We hypothesized that the effect of treatment on MENQOL score might be modified by baseline characteristics, specifically those related to sexual function. We assessed the interaction between treatment assignment and each baseline characteristic (reporting pain with sex as the most bothersome symptom and baseline FSFI [<median; !median]) within the repeated measures regression models. A sensitivity analysis evaluated intervention effects in models including only women who were adherent to treatment, defined as 80% or more medication use.
The planned sample size of the trial was determined by the primary trial endpoints. Reported P values were based on the Wald statistic, with two-sided P value of less than 0.05. Analyses were conducted using SAS Version 9.4 (SAS Institute, Cary, NC).
RESULTS
Three hundred two women were randomized to receive vaginal estradiol tablet plus placebo gel (n ¼ 102), placebo tablet plus vaginal moisturizer (n ¼ 100), or dual placebo (n ¼ 100) (Fig. 1) . Data on one or more domains of the MENQOL were available on 301 women (>99%) at baseline and 298 (99%) at 4 and/or 12 weeks of follow-up. Similarly for the PHQ-8 and GAD-7, data were available on 301 (>99%) women at baseline and 297 (97%) at follow-up.
Baseline characteristics were comparable between groups ( Table 1) . The mean age of study participants was 61 years; 88% were white and 85% were married or partnered. The most commonly reported most bothersome symptom was pain with vaginal penetration (182 [60%]). The majority of women (81%) were sexually active: 67% with a male partner, 1% with a female partner, and 44% self-stimulation. Mean (SD) total MENQOL score overall was 3.3 (SD 3.1); 70 women (23.3%) had PHQ-8 scores indicating mild depressive symptoms and 18 (6.0%) had scores indicating moderate-severe depressive symptoms; 70 (23.3%) had GAD-7 scores indicating mild anxiety; and 28 (9.3%) had scores indicating moderate anxiety.
At completion of the trial, among women with both baseline and follow-up MENQOL data, 83 of 100 (83%) women randomized to estradiol tablets returned their tablets for counting and were more than 80% adherent, compared to 80 of 99 (80%) women randomized to placebo tablets. Seventy-four of 99 (74%) women randomized to vaginal moisturizer returned their gel for weighing and were more than 80% adherent, compared to 79 of 99 (79%) of women randomized to placebo gel.
Effect of treatment assignment on total MENQOL scale and domain subscales
Total MENQOL scores declined, that is, menopauserelated QOL improved, in all treatment groups (Table 2) . Treatment with vaginal estradiol plus placebo gel resulted in significantly greater improvement in MENQOL scores compared to dual placebo (mean difference between groups at 12 weeks of À0.3 (95% confidence interval [CI] À0.5, 0.0; P ¼ 0.01) ( Table 2) . A statistically significant treatment group difference favoring the vaginal estradiol group was also observed for the sexual function domain (Table 2 ) (mean difference at 12 weeks of À0.4 (95% CI À1.0, 0.1; P ¼ 0.005) but not for any of the other domains (Table 2) . Treatment with vaginal moisturizer plus placebo tablet did not result in greater improvement compared to dual placebo in total MENQOL scores (mean difference between groups at 12 weeks of 0.2; 95% CI À0.1, 0.4; P ¼ 0.38) or in any of the four domains of the MENQOL (Table 2) .
Results were similar among adherent women (results not shown). We found no evidence of interactions between treatment assignment and selected characteristics (ie, presence or absence of sexual function-related most bothersome symptom and baseline FSFI) on total MENQOL score or sexual function domain score (data not shown).
Effect of treatment assignment on depressive symptoms and anxiety
The mean PHQ-8 score at baseline was 3.5 (SD 3.8). PHQ-8 scores improved in all treatment groups at week 12 but there were no statistically significant differences between vaginal estrogen and placebo gel versus dual placebo or between vaginal moisturizer and placebo tablet versus dual placebo (Table 3) . Similarly, there were no statistically significant differences between either active arm compared with dual placebo in GAD-7 change from baseline scores at week 12.
Results were similar among adherent women (data not shown).
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DISCUSSION
In this double-blind placebo controlled randomized trial studying postmenopausal women with moderate-severe vulvovaginal symptoms, women in all three treatment groups had small improvements in total menopause-related QOL over 12 weeks. Treatment with low-dose vaginal estradiol plus placebo gel improved total QOL and the sexual function domain of the MENQOL more than dual placebo. Treatment with a vaginal moisturizer and placebo tablet did not improve overall menopause-specific QOL or any of its domains more than dual placebo. Compared with placebo, neither vaginal estrogen nor vaginal moisturizer had greater effects on depressive symptoms or anxiety symptoms.
Previous trials of vaginal treatments for postmenopausal vulvovaginal complaints have focused on vaginal symptoms and sexual function as outcomes; few report a measure of QOL. Similar to the present study, randomized trials of the novel intravaginal agent, prasterone, and of an oral agent (bazedoxifene/conjugated estrogen), in women with vulvovaginal symptoms, observed greater improvement in total MENQOL and sexual function domain scores relative to placebo. Treatment with bazedoxifene/conjugated estrogen resulted in a difference in the mean improvement in total MENQOL scores compared to placebo of À0.4 to À0.5, depending on the dose of the estrogen (0.45 or 0.625 mg); improvement in the sexual function domain was approximately 0.6 to 0.7 points greater with active treatment compared to placebo. 28 Similarly, treatment with intravaginal prasterone resulted in a mean difference in improvement in total MENQOL compared to placebo ranging from À0.2 to À0.55, depending on the dose of prasterone; the sexual function domain improved 0.6 to 1.2 29 
No significant differences observed between intervention and placebo groups. 
DIEM ET AL
weeks, primarily due to improvements in physical domains as opposed to mental domains. 31 A case series of a novel intravaginal estriol/progesterone suppository reported improvement from baseline in MENQOL during 6 months, largely due to improvements in the sexual function domain, but this investigation is limited by the absence of a comparable control group. 32 Although small, the magnitude of the effect of vaginal estradiol on total MENQOL in our study (À0.3 [95% CI À0.5, 0.0]) is similar to that observed for low-dose oral 17-beta estradiol 0.5 mg/day (À0.4 [95% CI À0.7, À0.2]) in a previous trial conducted in postmenopausal women with bothersome hot flashes. 33 In that trial, the improvement in total MENQOL was associated with changes in three of the four domains, with the exception of psychosocial.
Of note, neither low-dose vaginal estradiol nor vaginal moisturizer had a greater impact than placebo on most bothersome vulvovaginal symptom severity or sexual functioning as measured by the FSFI in the primary trial analyses. 21 However, in this secondary analysis of trial data, we did observe a significantly larger improvement in the sexual function domain of the MENQOL among women assigned to vaginal estradiol and placebo gel. The three questions on the MENQOL regarding sexual functioning ask how much the responder has been bothered by a decrease in sexual desire, vaginal dryness during intercourse, and avoiding intimacy; thus, improvements reflect feeling less bothered on these dimensions. In contrast, the FSFI's 19 questions are more detailed and many ask responders to describe how often they felt sexual desire or interest, felt sexually aroused, were satisfied with their arousal during sexual activity, became lubricated during sexual activity, and experienced pain with vaginal penetration. These questions, which focus on frequency of sexual feelings, activity, and satisfaction, capture different aspects of sexual function than the MENQOL. The lack of alignment of the null treatment effects on the FSFI with modest treatment effects of vaginal estradiol on total and sexual MENQOL scores 
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suggests that different information about sexual QOL is detected when women are asked to provide a personal assessment of how much they are bothered by changes in sexual desire, vaginal dryness during intercourse, and avoiding intimacy. The implication is that multiple approaches to measuring sexual QOL are needed when assessing interventions to improve vaginal dryness or dyspareunia. We did not observe effects of vaginal estradiol or vaginal moisturizer, as compared to placebo, on anxiety or depressive symptoms. The causal paths affecting anxiety and depression symptoms are complex and variable. Therapies directed at vaginal symptoms are most likely to improve symptoms such as dyspareunia or dryness, which in turn may improve sexual function. Twelve weeks of treatment with modest improvements in overall and sexual QOL may not be sufficient to reverse longer-term effects of sexual problems on mood or anxiety. Alternatively, the psychosocial underpinnings of depression and anxiety symptoms may not be related to sexual problems in many women, or the mood symptoms may be contributing to sexual problems (reverse causation). In addition, very few women in our trial had moderate or severe levels of depression or anxiety, making it difficult to measure improvements in these parameters.
Strengths of this trial include the use of reliable and valid measures of menopause-related QOL and mood symptoms, use of placebos for both the vaginal estradiol and the vaginal moisturizer, and excellent participant retention and medication adherence. The study was not designed to compare the vaginal estradiol to vaginal moisturizer interventions directly.
CONCLUSIONS
Our results suggest that treatment with vaginal estradiol tablets in women with bothersome vulvovaginal symptoms improves overall menopause-related QOL more than placebo treatment. We did not observe a similar effect for a vaginal moisturizer. These results suggest that there may be modest benefit of treatment with vaginal estradiol tablets for improving aspects of sexual function captured in the MENQOL. Other considerations such as cost, ease of obtaining treatment, and personal preferences regarding vaginal treatment options may influence individual therapeutic choices.
